NOT FOR REPRINT
New treatments for people with a rare form of heart failure are in the pipeline
Commentary May 06, 2026 at 09:07 AM
Share & Print
What You Need To Know
- Transthyretin-mediated amyloid cardiomyopathy is a progressive form of heart failure.
- As many as 58,000 U.S. patients may suffer from the condition.
- Researchers want to edit the genes that cause the condition.
More From HR Executive
NOT FOR REPRINT
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.